Academic Journal
Προβολή σε EDS
Συνδεδεμένο Πλήρες Κείμενο

Antibody-drug conjugates in breast cancer.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Antibody-drug conjugates in breast cancer.
Συγγραφείς: Sakach EA; Winship Cancer Institute, Emory University, Atlanta, Georgia, USA., Meisel JL; Winship Cancer Institute, Emory University, Atlanta, Georgia, USA., McArthur HL; UT Southwestern Medical Center, Dallas, Texas, USA.
Πηγή: Cancer [Cancer] 2026 Jun 01; Vol. 132 Suppl 1, pp. e70420.
Τύπος έκδοσης: Journal Article; Review
Γλώσσα: English
Στοιχεία περιοδικού: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE
Imprint Name(s): Publication: <2005- >: Hoboken, NJ : Wiley
Original Publication: New York [etc.] Published for the American Cancer Society by J. Wiley [etc.]
Ιατρικοί όροι (MeSH): Breast Neoplasms*/drug therapy , Breast Neoplasms*/immunology , Breast Neoplasms*/pathology , Immunoconjugates*/therapeutic use , Antineoplastic Agents*/therapeutic use , Antineoplastic Agents, Immunological*/therapeutic use, Humans ; Female ; Animals
Περίληψη: Antibody-drug conjugates (ADCs) have rapidly changed the breast cancer treatment landscape. The unique technology allows for targeted delivery of a cytotoxic payload to cancer cells expressing a specific antigen, thereby delivering high cytotoxic loads while decreasing off-target effects. Efforts to improve ADC technology through optimization of the antibody, cytotoxic payload, and chemical linkers are ongoing. Novel target antigens are also being explored. Clinically, given the success of ADCs in the treatment of metastatic disease, efforts are ongoing to move these therapies into the early-stage setting with the aim of improving outcomes and increasing the likelihood of cure.
(© 2026 American Cancer Society.)
References: Diéras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2‐positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open‐label, phase 3 trial. Lancet Oncol. 2017;18(6):732‐742. doi:10.1016/s1470‐2045(17)30312‐1.
Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2‐positive advanced breast cancer. N Engl J Med. 2012;367(19):1783‐1791. doi:10.1056/nejmoa1209124.
Saura C, Modi S, Krop I, et al. Trastuzumab deruxtecan in previously treated patients with HER2‐positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY‐Breast01). Ann Oncol. 2024;35(3):302‐307. doi:10.1016/j.annonc.2023.12.001.
André F, Hee Park Y, Kim SB, et al. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2‐positive metastatic breast cancer (DESTINY‐Breast02): a randomised, open‐label, multicentre, phase 3 trial. Lancet. 2023;401(10390):1773‐1785. doi:10.1016/s0140‐6736(23)00725‐0.
Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2‐positive metastatic breast cancer: updated results from DESTINY‐Breast03, a randomised, open‐label, phase 3 trial. Lancet. 2023;401(10371):105‐117. doi:10.1016/s0140‐6736(22)02420‐5.
Tolaney SM, Jiang Z, Zhang Q, et al. Trastuzumab deruxtecan (T‐DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first‐line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY‐Breast09. J Clin Oncol. 2025;43(suppl 17):LBA1008. doi:10.1200/jco.2025.43.17_suppl.lba1008.
Rugo HS, Bardia A, Marmé F, et al. Primary results from TROPiCS‐02: a randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2‐negative (HR+/HER2‐) advanced breast cancer. J Clin Oncol. 2022;40(suppl 17):LBA1001. doi:10.1200/jco.2022.40.17_suppl.lba1001.
Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. Genes Cancer. 2015;6(3‐4):84‐105. doi:10.18632/genesandcancer.40.
Jhaveri1, YP, K L, Barrios3 C, Curigliano4 G, et al. Sacituzumab govitecan vs chemotherapy as first therapy after endocrine therapy in HR+/HER2− (IHC 0, 1+, 2+/ISH−) metastatic breast cancer: primary results from ASCENT‐07. Paper presented at: SABCS; 2025, San Antonio, TX.
Cortés J, Punie K, Barrios C, et al. Sacituzumab govitecan in untreated, advanced triple‐negative breast cancer. N Engl J Med. 2025;393(19):1912‐1925. doi:10.1056/NEJMoa2511734.
Bardia A, Punie K, Barrios C, et al. 275TiP ASCENT‐03: phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in first‐line (1L) metastatic triple‐negative breast cancer (mTNBC). Ann Oncol. 2022;33:S663‐S664. doi:10.1016/j.annonc.2022.07.1859.
Cortés J, Punie K, Barrios C, et al. Sacituzumab govitecan in untreated, advanced triple‐negative breast cancer. N Engl J Med. 2025;393(19):1912‐1925. doi:10.1056/nejmoa2511734.
Cortes J, Rugo HS, Cescon DW, et al. Pembrolizumab plus chemotherapy in advanced triple‐negative breast cancer. N Engl J Med. 2022;387(3):217‐226. doi:10.1056/nejmoa2202809.
Tolaney SM, de Azambuja E, Kalinsky K, et al. Sacituzumab govitecan plus pembrolizumab for advanced triple‐negative breast cancer. N Engl J Med. 2026;394(4):354‐366. doi:10.1056/nejmoa2508959.
Dent R, Shao Z, Schmid P, et al. First‐line datopotamab deruxtecan (Dato‐DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple‐negative breast cancer (TNBC) for whom immunotherapy was not an option: primary results from the randomised, phase 3 TROPION‐Breast02 trial. Paper presented at: ESMO; 2025.
Schmid P, Oliveira M, O’Shaughnessy J, et al. TROPION‐Breast05: a randomized phase III study of Dato‐DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD‐L1‐high locally recurrent inoperable or metastatic triple‐negative breast cancer. Ther Adv Med Oncol. 2025;17:17588359251327992. doi:10.1177/17588359251327992.
Tarantino P, Zhou N, Li T, et al. Abstract PS1‐09‐02: intracranial activity of datopotamab deruxtecan (Dato‐DXd) for patients with HER2‐negative breast cancer and leptomeningeal disease (LMD): results from Cohort C of the DATO‐BASE phase 2 trial. Clin Cancer Res. 2026;32(suppl 4):PS1‐PS9. doi:10.1158/1557‐3265.sabcs25‐ps1‐09‐02.
Ogitani Y, Aida T, Hagihara K, et al. DS‐8201a, a novel HER2‐targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T‐DM1. Clin Cancer Res. 2016;22(20):5097‐5108. doi:10.1158/1078‐0432.ccr‐15‐2822.
Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107(7):1039‐1046. doi:10.1111/cas.12966.
Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2‐positive breast cancer with trastuzumab‐DM1, an antibody–cytotoxic drug conjugate. Cancer Res. 2008;68(22):9280‐9290. doi:10.1158/0008‐5472.can‐08‐1776.
Nakada T, Masuda T, Naito H, et al. Novel antibody drug conjugates containing exatecan derivative‐based cytotoxic payloads. Bioorg Med Chem Lett. 2016;26(6):1542‐1545. doi:10.1016/j.bmcl.2016.02.020.
Tamura K, Tsurutani J, Takahashi S, et al. Trastuzumab deruxtecan (DS‐8201a) in patients with advanced HER2‐positive breast cancer previously treated with trastuzumab emtansine: a dose‐expansion, phase 1 study. Lancet Oncol. 2019;20(6):816‐826. doi:10.1016/s1470‐2045(19)30097‐x.
Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2‐positive breast cancer. N Engl J Med. 2020;382(7):610‐621. doi:10.1056/nejmoa1914510.
Cortés J, Kim SB, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386(12):1143‐1154. doi:10.1056/nejmoa2115022.
Curigliano G, Dunton K, Rosenlund M, et al. Patient‐reported outcomes and hospitalization data in patients with HER2‐positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY‐Breast03 study. Ann Oncol. 2023;34(7):569‐577. doi:10.1016/j.annonc.2023.04.516.
Metzger O, Mandrekar S, Goel S, et al. Palbociclib for hormone‐receptor‐positive, HER2‐positive advanced breast cancer. N Engl J Med. 2026;394(5):451‐462. doi:10.1056/NEJMoa2511218.
Dieras V, Curigliano G, Martin M, et al. HER2CLIMB‐05: a phase III study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as first‐line maintenance therapy for HER2+ metastatic breast cancer. J Clin Oncol. Published online December 10, 2025. doi:10.1200/JCO‐25‐02600.
Cortés JJG‐M, Juan A, Gabriele, et al. P5‐03‐11; SESS‐671 ‐ DEMETHER: a single‐arm phase II trial to evaluate the efficacy & safety of subcutaneous pertuzumab & trastuzumab maintenance after induction treatment w/trastuzumab deruxtecan (T‐DXd) for previously untreated HER2‐positive advanced breast cancer. In: San Antonio Breast Cancer Symposium; 2024.
Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2‐positive metastatic breast cancer (CLEOPATRA): end‐of‐study results from a double‐blind, randomised, placebo‐controlled, phase 3 study. Lancet Oncol. 2020;21(4):519‐530. doi:10.1016/s1470‐2045(19)30863‐0.
Baselga J, Cortés J, Im SA, et al. Biomarker analyses in CLEOPATRA: a phase III, placebo‐controlled study of pertuzumab in human epidermal growth factor receptor 2‐positive, first‐line metastatic breast cancer. J Clin Oncol. 2014;32(33):3753‐3761. doi:10.1200/jco.2013.54.5384.
Pedram Razavi LC, Jimmitti T, An J, et al. Circulating tumor DNA (ctDNA) dynamics as a predictor of treatment response in metastatic breast cancer (mBC). ASCO. 2025. Abstract 1011.
Andre F, Hamilton EP, Loi S, et al. DESTINY‐Breast07: dose‐expansion interim analysis of T‐DXd monotherapy and T‐DXd + pertuzumab in patients with previously untreated HER2+ mBC. J Clin Oncol. 2024;42(suppl 16):1009. doi:10.1200/jco.2024.42.16_suppl.1009.
Minckwitz Gv., Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2‐positive breast cancer. N Engl J Med. 2019;380(7):617‐628. doi:10.1056/nejmoa1814017.
Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2‐low advanced breast cancer. N Engl J Med. 2022;387(1):9‐20. doi:10.1056/nejmoa2203690.
Bardia A, Hu X, Dent R, et al. Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med. 2024;391(22):2110‐2122. doi:10.1056/nejmoa2407086.
Harbeck N, Modi S, Pusztai L, et al. Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high‐risk HER2‐positive early breast cancer (DESTINY‐Breast11): a randomised, open‐label, multicentre, phase III trial. Ann Oncol. 2026;37(2):166‐179. doi:10.1016/j.annonc.2025.10.019.
Geyer CE, Untch M, Huang CS, et al. Survival with trastuzumab emtansine in residual HER2‐positive breast cancer. N Engl J Med. 2025;392(3):249‐257. doi:10.1056/nejmoa2406070.
Geyer CE Jr, Untch M, Prat A, et al. Abstract OT1‐02‐03: trastuzumab deruxtecan (T‐DXd; DS‐8201) vs trastuzumab emtansine (T‐DM1) in high‐risk patients with HER2‐positive, residual invasive early breast cancer after neoadjuvant therapy: a randomized, phase 3 trial (DESTINY‐Breast05). Cancer Res. 2022;82(suppl 4):OT1‐03. doi:10.1158/1538‐7445.sabcs21‐ot1‐02‐03.
Loibl S, Park YH, Shao Z, et al. Trastuzumab deruxtecan in residual HER2‐positive early breast cancer. N Engl J Med. 2026;394(9):845‐857. doi:10.1056/nejmoa2514661.
Harbeck N, Modi S, Pusztai L, et al. Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high‐risk HER2‐positive early breast cancer (DESTINY‐Breast11): a randomised, open‐label, multicentre, phase III trial. Ann Oncol. 2026;37(2):166‐179. doi:10.1016/j.annonc.2025.10.019.
Tolaney SM, Bardia A, Marmé F, et al. Final overall survival (OS) analysis from the phase 3 TROPiCS‐02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2‐negative (HR+/HER2–) metastatic breast cancer (mBC). J Clin Oncol. 2023;41(suppl 16):1003. doi:10.1200/jco.2023.41.16_suppl.1003.
Rugo HS, Schmid P, Tolaney SM, et al. Health‐related quality of life with sacituzumab govitecan in HR+/HER2− metastatic breast cancer in the phase III TROPiCS‐02 trial. Oncologist. 2024;29(9):768‐779. doi:10.1093/oncolo/oyae088.
Rugo H, Cortés J, Curigliano G, et al. Abstract PO1‐05‐09: ASCENT‐07: a phase 3, randomized, open‐label study of sacituzumab govitecan versus treatment of physician’s choice in patients with HR+/HER2– inoperable, locally advanced, or metastatic breast cancer post‐endocrine therapy. Cancer Res. 2024;84(suppl 9):PO1‐09. doi:10.1158/1538‐7445.sabcs23‐po1‐05‐09.
Bardia A, Jhaveri K, Im SA, et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor–positive human epidermal growth factor receptor 2–negative breast cancer: primary results from TROPION‐Breast01. J Clin Oncol. 2025;43(3):285‐296. doi:10.1200/jco.24.00920.
Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple‐negative breast cancer. N Engl J Med. 2021;384(16):1529‐1541. doi:10.1056/nejmoa2028485.
Tolaney SAE, Kalinsky K. Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD‐L1–positive advanced triple‐negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT‐04/KEYNOTE‐D19 study. J Clin Oncol. 2025;43(suppl 17):LBA109. doi:10.1200/JCO.2025.43.17_suppl.LBA109.
Mosele F, Deluche E, Lusque A, et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat Med. 2023;29(8):2110‐2120. doi:10.1038/s41591‐023‐02478‐2.
Grinda T, Morganti S, Hsu L, et al. Real‐World outcomes with sacituzumab govitecan among breast cancer patients with central nervous system metastases. NPJ Breast Cancer. 2025;11(1):22. doi:10.1038/s41523‐025‐00736‐9.
Spring LM, Tolaney S, Fell G, et al. Response‐guided neoadjuvant sacituzumab govitecan for localized triple‐negative breast cancer: results from the NeoSTAR trial. Ann Oncol. 2024;35(3):293‐301. doi:10.1016/j.annonc.2023.11.018.
Abelman RO, McLaughlin S, Fell GG, et al. A phase 2 study of response‐guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG/P) in patients with early‐stage triple‐negative breast cancer: results from the NeoSTAR trial. J Clin Oncol. 2025;43(suppl 16):511. doi:10.1200/jco.2025.43.16_suppl.511.
Marmé F, Stickeler E, Furlanetto J, et al. Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2‐negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA. J Clin Oncol. 2021;39(suppl 15):TPS602. doi:10.1200/jco.2021.39.15_suppl.tps602.
Tolaney SM, DeMichele A, Takano T, et al. ASCENT‐05/OptimICE‐RD (AFT‐65): phase 3, randomized, open‐label study of adjuvant sacituzumab govitecan (SG) + pembrolizumab (pembro) vs pembro ± capecitabine (cape) in patients (pts) with triple‐negative breast cancer (TNBC) and residual disease after neoadjuvant therapy (NAT) and surgery. J Clin Oncol. 2023;41(suppl 16):TPS619. doi:10.1200/jco.2023.41.16_suppl.tps619.
Bardia A, Pusztai L, Albain K, et al. TROPION‐Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple‐negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Ther Adv Med Oncol. 2024;16:17588359241248336. doi:10.1177/17588359241248336.
Huppert LA, Mahtani R, Fisch S, et al. Multicenter retrospective cohort study of the sequential use of the antibody‐drug conjugates (ADCs) trastuzumab deruxtecan (T‐DXd) and sacituzumab govitecan (SG) in patients with HER2‐low metastatic breast cancer (MBC). NPJ Breast Cancer. 2025;11(1):34. doi:10.1038/s41523‐025‐00748‐5.
Mai N, Klar M, Ferraro E, Bromberg M. Real world ourcomes of sequential ADC therapy in metastatic breast cancer: patients treated with sacituzumab govitecan and trastuzumab deruxtecan. Paper presented at: ASCO 2024. 2024.
Rachel Occhiogrosso Abelman LS, Fell GG, Ryan P, et al. Sequential use of antibody‐drug conjugate after antibody‐drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study. Paper presented at: ASCO. 2023, 2023.
Tarantino P, Lee D, Foldi J, Soulos P. Real‐world efficacy of immediate subsequent lines of therapy after trastuzumab deruxtecan (T‐DXd) in patients with metastatic breast cancer (MBC) – retrospective study from the nationwide Flatiron database. Paper presented at: SABCS; 2024; San Antonio, TX.
Wang J, Liu Y, Zhang Q, et al. Disitamab vedotin, a HER2‐directed antibody‐drug conjugate, in patients with HER2‐overexpression and HER2‐low advanced breast cancer: a phase I/Ib study. Cancer Commun. 2024;44(7):833‐851. doi:10.1002/cac2.12577.
Wu Y, Mol H, Sun X, Peng X, Ma F. Disitamab vedotin (RC48) for previously treated HER2‐expressing metastatic breast cancer with abnormal activation of PAM pathway: Results from a single‐arm, prospective phase II clinical trial. Ann Oncol. 2024;35(suppl 2):S379.
Krop IE, Masuda N, Mukohara T, et al. Patritumab deruxtecan (HER3‐DXd), a human epidermal growth factor receptor 3–directed antibody‐drug conjugate, in patients with previously treated human epidermal growth factor receptor 3–expressing metastatic breast cancer: a multicenter, phase I/II trial. J Clin Oncol. 2023;41(36):5550‐5560. doi:10.1200/jco.23.00882.
O'Shaughnessy J, Collins J, Yao L, et al. HERTHENA‐Breast03: a phase 2, randomized, open‐label study evaluating neoadjuvant patritumab deruxtecan + pembrolizumab before or after pembrolizumab + chemotherapy for early‐stage TNBC or HR‐low+/HER2− breast cancer. J Clin Oncol. 2025;43(suppl 16):TPS629.
Hamilton E, H.H., Abuhadra N, et al. Clinical activity of emiltatug ledadotin (Emi‐Le), a B7‐H4‐directed ADC, in patients with TNBC who received at least one prior topoisomerase‐1 inhibitor (Topo‐1) ADC. Paper presented at: ESMO Breast Congress; 2025; Munich, Germany.
Yin Y, Fan Y, Ouyang Q, et al. Sacituzumab tirumotecan in previously treated metastatic triple‐negative breast cancer: a randomized phase 3 trial. Nat Med. 2025;31(6):1969‐1975. doi:10.1038/s41591‐025‐03630‐w.
Niquille DL, Fitzgerald KM, Gera N. Biparatopic antibodies: therapeutic applications and prospects. mAbs. 2024;16(1):2310890. doi:10.1080/19420862.2024.2310890.
Hu X, Wang L, Zhang J, et al. ACE‐Breast‐02: a pivotal phase II/III trial of ARX788, a novel anti‐HER2 antibody‐drug conjugate (ADC), versus lapatinib plus capecitabine for HER2+ advanced breast cancer (ABC). J Clin Oncol. 2024;42(suppl 16):1020. doi:10.1200/jco.2024.42.16_suppl.1020.
Tripathy D, Ali K, Agrawal L, et al. ACE‐BREAST‐03: a phase 2 trial evaluating ARX788, an anti‐HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T‐DXd). J Clin Oncol. 2024;42(suppl 16):TPS1123. doi:10.1200/jco.2024.42.16_suppl.tps1123.
Keri D, Walker M, Singh I, Nishikawa K, Garces F. Next generation of multispecific antibody engineering. Antib Ther. 2023;7(1):37‐52. doi:10.1093/abt/tbad027.
Lee H, Kim B, Ko Y, et al. Enhancing the bystander effect of antibody‐drug conjugate by using a novel caspase‐3 cleavable peptide linker to overcome tumor heterogeneity. J Contr Release. 2025;382:113738.
Wang R, Hu B, Pan Z, et al. Antibody–drug conjugates (ADCs): current and future biopharmaceuticals. J Hematol Oncol. 2025;18(1):51. doi:10.1186/s13045‐025‐01704‐3.
Wei Q, Li P, Yang T, et al. The promise and challenges of combination therapies with antibody‐drug conjugates in solid tumors. J Hematol Oncol. 2024;17(1):1. doi:10.1186/s13045‐023‐01509‐2.
Tsuchikama K, Anami Y, Ha SYY, Yamazaki CM. Exploring the next generation of antibody‐drug conjugates. Nat Rev Clin Oncol. 2024;21(3):203‐223. doi:10.1038/s41571‐023‐00850‐2.
Contributed Indexing: Keywords: administration and dosage; adverse effects; drug effects; drug therapy; pharmacology
Substance Nomenclature: 0 (Immunoconjugates)
0 (Antineoplastic Agents)
0 (Antineoplastic Agents, Immunological)
Entry Date(s): Date Created: 20260601 Date Completed: 20260603 Latest Revision: 20260603
Update Code: 20260604
DOI: 10.1002/cncr.70420
PMID: 42225999
Βάση Δεδομένων: MEDLINE
Περιγραφή
ISSN:1097-0142
DOI:10.1002/cncr.70420